Project Grant R01DA058089
- This $197,500 Project Grant awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), is funded under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is being used to establish and deploy a Massively Parallel Reporter Assay (MPRA) in mouse brains to measure regulatory activity and the effect of opioid addiction-associated human genetic variants. The R21 phase will validate the MPRA method in primary neurons and brain tissues,...
- This Project Grant award of $436,050, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research at Duke University to investigate cell type and circuit-specific epigenetic mechanisms underlying cocaine addiction. The goal is to utilize a mouse model of cocaine addiction to better understand how cocaine-induced molecular changes in specific brain regions and cell types lead to the rewiring of neural circuits that...
- The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), awarded a $398,137 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Boston Interactome LLC. The grant, awarded on May 1, 2025, is for the development of high-precision epigenetic therapeutics to treat opioid use disorder (OUD). The project aims to identify small-molecule modulators that can disrupt the protein-protein interactions of the epigenetic G9A complex, which...
- This federal Project Grant award of $126,660, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research at the University of California, San Diego (UCSD) to investigate the role of tandem repeats and structural variants in addiction-related behaviors using heterogeneous stock rats. The key products and services to be delivered under this 3-year grant, which runs from Sep 30, 2025 to Jun 30, 2028, include:...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The grantee, Epivario Inc., a for-profit biotechnology research organization, will screen a new class of ACSS2 inhibitors and evaluate their efficacy in preclinical animal models of OUD. Specifically, the $275,253 award will support...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $405,625.00 to Florida International University to investigate the potential benefits of the autophagy activator TFEB in mitigating opioid use disorder (OUD) and overdose in mice. The research aims to evaluate how TFEB overexpression or knockdown impacts opioid-induced effects on mu-opioid receptor desensitization, internalization, and...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $272,395.00 to The Regents of the University of California, San Francisco (UCSF) to conduct research on "Biochemically Counteracting Maladaptive Functions of G9A/GLP in Addiction." The research aims to develop methods for targeting the activity of the epigenetic modifiers G9A and GLP, which have been implicated in the...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $787,594 to the Icahn School of Medicine at Mount Sinai to conduct research on the "Cortical Mechanisms of Opioid Reinforcement." The research aims to better understand the molecular, cellular, and circuit-based mechanisms underlying opioid use disorder (OUD). Key objectives include investigating the role of a specific population of...
- This federal Project Grant award of $180,606.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund research at the Icahn School of Medicine at Mount Sinai to investigate the interplay between drug-induced long-term synaptic proteomic adaptations and the underlying transcriptional responses that drive these adaptations in a cell-type and circuit-specific manner within the brain's reward regions. The research aims to...
- This federal Project Grant award of $476,123 from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), is supporting research under the Drug Use and Addiction Research Programs (CFDA 93.279). The goal is to leverage machine learning and genomic technologies to investigate how genetic variants impact the circadian regulation of gene expression and its relationship to substance use disorders, including opioid use disorder. The research involves conducting...
REPROGRAMMING KZFP FUNCTION TO UNDERSTAND DRUG-SPECIFIC TRANSCRIPTION AND BEHAVIOR - PROJECT SUMMARY IN THIS REVISED R01, WE PROPOSE TO USE NOVEL SYNTHETIC TRANSCRIPTION FACTORS (TFS) DELIVERED TO THE MOUSE NUCLEUS ACCUMBENS (NAC), A KEY BRAIN REWARD REGION, TO UNCOVER AND MANIPULATE THE CELL-TYPE-SPECIFIC BRAIN MOLECULAR PROCESSES THAT DISTINGUISH STIMULANT VERSUS OPIOID ADDICTION. THIS WILL ENABLE US TO GENERATE KNOWLEDGE CRITICAL FOR THE DESIGN OF THE NEXT GENERATION OF DRUG-SPECIFIC, ANTI-ADDICTION MEDICATIONS. AN EXISTING BODY OF LITERATURE SUGGESTS THAT, IN RESPONSE TO USE OF ADDICTIVE DRUGS, THE FUNCTION OF KEY TFS WITHIN THE CELLS THAT COMPRISE BRAIN REWARD REGIONS DRIVE TRANSCRIPTIONAL ADAPTATIONS AND LASTING CHANGES IN DRUG USE BEHAVIORS. PRELIMINARY AND PUBLISHED DATA POINT TO NAC ZFP189, A MEMBER OF THE KRAB-DOMAIN CONTAINING ZINC-FINGER (KZFP) TF FAMILY, AS HIGHLY SENSITIVE TO COCAINE USE, AND CAUSAL IN WORSENING STIMULANT- BUT NOT OPIOID-RELATED BEHAVIORS. THIS SUGGESTS THAT THE NAC ZFP189 TF IS UNIQUELY SENSITIVE TO, AND CONTRIBUTES TO, THE BRAIN ADAPTATIONS THAT WORSEN STIMULANT ADDICTION. HERE, WE HAVE REPROGRAMMED ZFP189 TO CREATE SYNTHETIC TFS, EACH POSSESSING FUNCTIONAL MOIETIES THAT EXERT DISTINCT FORMS OF TRANSCRIPTIONAL CONTROL AT IN VIVO TARGET GENES. THIS ENABLES US TO UNCOVER HOW THE STIMULANT VERSUS OPIOID USE EXPERIENCE DIFFERENTIALLY PRIMES THE EPIGENETIC STATUS OF NAC CELLS TO FACILITATE THE FUNCTION OF DRUG-SPECIFIC TFS. IN AIM 1 WE WILL VIRALLY DELIVER SYNTHETIC ZFP189 TFS TO THE NAC OF MICE, DOSE WITH REPEATED STIMULANT OR OPIOID TREATMENTS, AND PERFORM MULTIOME SINGLE NUCLEI ATAC AND RNA SEQUENCING. THIS WILL REVEAL THE BIOLOGICAL MECHANISMS THROUGH WHICH STIMULANT VERSUS OPIOID EXPOSURE ENABLES DRUG-SPECIFIC TF FUNCTION, THE TRANSCRIPTIONAL ADAPTATIONS THAT FACILITATE SPECIFIC DRUG ADDICTIONS, AND THE NAC CELL-TYPES IN WHICH THIS OCCURS. IN AIM 2, WE WILL VIRALLY DELIVER SYNTHETIC ZFP189 TFS TO MOUSE NAC AND INVESTIGATE THEIR CONTRIBUTION TO STIMULANT VERSUS OPIOID CONDITIONED AND DRUG SELF- ADMINISTRATION REWARD-RELATED BEHAVIORS. THIS WILL REVEAL HOW DRUG-SPECIFIC TRANSCRIPTIONAL NEUROADAPTATIONS MAY DIFFERENTIALLY DRIVE A WORSENING OF STIMULANT- VERSUS OPIOID-RELATED BEHAVIORS. LASTLY, IN AIM 3, WE WILL INTRODUCE NOVEL SYNTHETIC TF CO-FACTORS, CAPABLE OF RE-PROGRAMMING THE IN VIVO GENE-REGULATORY FUNCTION OF THE ENTIRE KZFP TF FAMILY, TO INTERROGATE HOW DISTINCT KZFP MEMBERS ARE RECRUITED TO WORSEN STIMULANT- VERSUS OPIOID ADDICTION. TO ACCOMPLISH THIS, WE WILL VIRALLY DELIVER VARIANTS OF THE KZFP CO-FACTOR, TRIM28, TO SIMULTANEOUSLY DYSREGULATE MEMBERS OF THE KZFP TF FAMILY WITHIN THE NAC. WE WILL PERFORM SELF-ADMINISTRATION FOR STIMULANTS AND OPIOIDS AND SUBJECT TISSUES TO SINGLE NUCLEI RNA SEQUENCING. THIS WILL UNCOVER THE COLLECTIVE CONTRIBUTION OF NAC KZFPS TO THE WORSENING OF STIMULANT AND OPIOID DRUG BEHAVIORS AND REVEAL THE KZFPS, AND THEIR REGULATED GENES, THAT MOST DRIVE THESE DAMAGING EFFECTS. TOGETHER, THIS RESEARCH WILL PROVIDE NEW APPROACHES TO IDENTIFY THE TF FUNCTIONS AT THE CORE OF SPECIFIC DRUG ADDICTIONS AND YIELD REFINED GENE CANDIDATES AS TARGETS FOR FUTURE DRUG-SPECIFIC MEDICATIONS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $52.5k | 4/10/25 | ||
| Not listed | $472.2k | 2/28/25 | ||
| Not listed | $472.2k | 2/28/25 | ||
| Not listed | $515.6k | 4/24/24 | ||
| Not listed | $515.6k | 4/24/24 |